Briar Alpert Named to UVM Board of Trustees
News Mar 14, 2016
As part of this six-year term, Mr. Alpert will advise and support UVM management on policy, budgets, strategic planning and other matters to ensure the University’s long-term vision and success.
Mr. Alpert has far-reaching ties with the University, having earned his MBA and a BS in mechanical engineering from UVM. Additionally, his father and BioTek’s founder, Dr. Norman Alpert, was an internationally recognized expert in cardiac hypertrophy and energetics while serving as Chairman of the Physiology Department at the University of Vermont Medical College.
Along with the UVM Board of Trustees, Mr. Alpert is the Vice Chairman & Chairman-Elect for the Analytical, Life Science & Diagnostics Association (ALDA), a Charter Member and Director of the Vermont Center of Emerging Technologies (VCET), and is a full member of the Vermont Academy of Science and Engineering (VASE) and Mechanical Engineering Honor Society.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE